Specifically, patients with age >65 years old, radiotherapy treatment, chemotherapy treatment, WHO IV tumor, cluster2, high immune score, primary tumor, and wild‐type IDH had a higher risk score (Figure S2A–H), and risk score was not significantly correlated with gender (Figure S2I). Here, IDH1 is linked to neoplasm.